RESUMO
Three controlled trials were carried out in patients with irritable bowel syndrome to assess the effectiveness of trimebutine in controlling the symptoms of abdominal distension, pain, flatulence, constipation, diarrhoea and dyspepsia. In the first two trials, it was shown that 200 mg trimebutine 3-times daily for 3 days produced rapid relief of symptoms and was significantly (p less than 0.001) more effective than placebo, but not significantly so when the dosage level was halved. In the third trial, the results showed that 200 mg trimebutine 3-times daily for 2 weeks was as effective as 100 mg mebeverine 4-times daily in relieving the major symptoms and in improving motility. No serious side-effects were reported with trimebutine at the dosage used.
Assuntos
Benzoatos/uso terapêutico , Doenças Funcionais do Colo/tratamento farmacológico , Trimebutina/uso terapêutico , Adulto , Idoso , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Fármacos Gastrointestinais/efeitos adversos , Fármacos Gastrointestinais/uso terapêutico , Humanos , Masculino , Pessoa de Meia-Idade , Fenetilaminas/uso terapêutico , Trimebutina/efeitos adversosRESUMO
In a double-blind crossover trial of three days duration on each drug, trimebutine in a dose of 200 mg three times daily was significantly more effective than placebo in relieving the symptoms of mild to moderate degrees of spastic colon (p less than 0.001). The only side-effect necessitating discontinuation of treatment was one case of vomiting.
